Evaluation of prognostic markers in severe drug-induced liver disease

World Journal of Gastroenterology

Volumn 13, Issue 4, 2007, Pages 628-632

  Li, Bo ^a   Wang, Zhi ^b   Fang, Jian Jiang ^a   Xu, Ci Yi ^a   Chen, Wei Xing ^c  

^a Lihuili Hospital   (China)

^b Ningbo Women and Children's Hospital   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Drug induced liver disease; Mortality; Prognosis; Prognostic marker

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC ANALGESIC AGENT; ANTITHYROID AGENT; ANTIULCER AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARDIOVASCULAR AGENT; HERBACEOUS AGENT; HYPNOTIC SEDATIVE AGENT; IMMUNOSUPPRESSIVE AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; FETOTOXICITY; HERBAL MEDICINE; HUMAN; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 33846826961     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i4.628     Document Type: Article

References (12)

1. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-1271
2. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118-1127
3. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4: 73-96, vi
4. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302
5. Senior JR. Regulatory perspectives. In: Drug-Induced Liver Disease. Kaplowitz N, DeLeve LD, ets. New York: Marcel Dekker, 2003: 739-754
6. s Diseases of the Liver. 8th ed. Philadelphia:Lippincott-Raven Publishers, 1999: 973-1064
7. Davidson CS, Leevy CM, Chamberlayne EC, ets. Guidelines for Detection of Hepatotoxicity Due to Drugs and Chemicals. Fogarthy Conference, 1978. NIH publication no. 79-313. Washington, DC: US Government Printing Office, 1979
8. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
9. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276
10. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455
11. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-138
12. Ohmori S, Shiraki K, Inoue H, Okano H, Yamanaka T, Deguchi M, Sakai T, Takase K, Nakano T, Tameda Y. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology 2003; 50: 1531-1534